Skip to main content

Table 4 Reaction rates with rush mOIT

From: Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

Initial escalation day
Escalations performed 25
  Reactions 13 (52%)
  Mild (Grade 1) 13 (52%)
  Moderate (Grade 2) 0
  Severe (Grade 3) 0
Epinephrine use 0
Dose escalations
Doses administered 227
Reactions 13 (5.7%)
  Mild (Grade 1) 13 (5.7%)
  Moderate (Grade 2) 0
  Severe (Grade 3) 0
Median reaction rate [range] 0% [0–25]
Epinephrine use 0
Home dosing
Doses administered 7530
Reactions 401 (5.3%)
  Mild (Grade 1) 385 (5.1%)
  Moderate (Grade 2) 15 (0.2%)
  Severe (Grade 3) 1 (0.01%)
Median reaction rate [range] 3.2% [0.1-18.5]
Epinephrine use 1 (0.01%)